ClinicalTrials.gg

How we know

Every link on this study, and who decided it

The study on the left, the conditions and drugs this site links it to, and on each link the judgments that made or checked it, by day and by judge. The top row is the record itself: each new version seen since tracking began. Dashed lines are links the registry record does not make itself. Select a link to see everything judged on it, or a mark for one decision with its reason and evidence.

6 links0 made here, not in the record13 judgments2 judges (our rules as one)0 record changes seen
Claude Opus 5.5Our rules
Oct 19Oct 26Nov 2Nov 9Nov 16TodayNCT06747338A Phase III Study of KN026in Combination With HB1801± Carboplatin asNeoadjuvant Treatment forEarly or Locally AdvancedHER2-Positive Breast CancerShanghai JMT-Bio Inc.Phase 3 · active not recruitinRECORDThe record itselfVersions seen nightly since Sep 25, 2…›No new version seen since tracking began Sep 25, 2026.CONDITIONSBreast NeoplasmsNo longer in the registry's filing›Nov 14 · Our condition-kind rule · Finest filed termAs of now · Our main-condition rule (R9) · Main conditionMain conditionDRUGSAnbenitamabEntry “KN026”, read by our name rule›Nov 2 · Claude Opus 5.5 · TestedNov 18 · Our role rule · TestedTestedDocetaxelEntry “HB1801”, read by our name rule›Nov 2 · Claude Opus 5.5 · TestedNov 18 · Our role rule · TestedNov 18 · Our role rule · ComparatorComparatorPertuzumabIntervention entry›Nov 2 · Claude Opus 5.5 · ComparatorNov 18 · Our role rule · ComparatorComparatorTrastuzumabIntervention entry›Nov 2 · Claude Opus 5.5 · ComparatorNov 18 · Our role rule · ComparatorComparatorCarboplatinIntervention entry›Nov 2 · Claude Opus 5.5 · ComparatorNov 18 · Our role rule · ComparatorComparator

Times are in your time zone; a day marked “day only” kept no time. The graph scrolls sideways on a narrow screen; every mark is also in the list below.

Anbenitamab

From the registry record2 judgments on this link
Role in the study, from the registry to what was judged
RegistryEntry “KN026”the record gives no role
→judged=agrees
How the 2 judgments split100%of judgments with a known value say Tested
Tested · 2

All judgments on this study

WhenLinkJudgeDecisionState
Nov 2AnbenitamabClaude Opus 5.5TestedCurrent
Nov 2DocetaxelClaude Opus 5.5TestedCurrent
Nov 2PertuzumabClaude Opus 5.5ComparatorCurrent
Nov 2TrastuzumabClaude Opus 5.5ComparatorCurrent
Nov 2CarboplatinClaude Opus 5.5ComparatorCurrent
Nov 14Breast NeoplasmsOur condition-kind ruleFinest filed termCurrent
Nov 18AnbenitamabOur role ruleTestedAgrees
Nov 18DocetaxelOur role ruleTestedAgrees
Nov 18DocetaxelOur role ruleComparatorCurrent
Nov 18PertuzumabOur role ruleComparatorAgrees
Nov 18TrastuzumabOur role ruleComparatorAgrees
Nov 18CarboplatinOur role ruleComparatorAgrees
As of nowBreast NeoplasmsOur main-condition rule (R9)Main conditionCurrent